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An association has been previously established between uncompensated diabetes mellitus and the loss of bone mineral density and/or quality.
In this study, we evaluated the effects of metformin on the growth and differentiation of osteoblasts in culture. Treatment of two osteoblast-like
cells (UMR106 and MC3T3E1) with metformin (25–500μM) for 24h led to a dose-dependent increase of cell proliferation. Metformin also
promoted osteoblastic differentiation: it increased type-I collagen production in both cell lines and stimulated alkaline phosphatase activity in
MC3T3E1 osteoblasts. In addition, metformin markedly increased the formation of nodules of mineralization in 3-week MC3T3E1 cultures.
Metformin induced activation and redistribution of phosphorylated extracellular signal-regulated kinase (P-ERK) in a transient manner, and dose-
dependently stimulated the expression of endothelial and inducible nitric oxide synthases (e/iNOS). These results show for the first time a direct
osteogenic effect of metformin on osteoblasts in culture, which could be mediated by activation/redistribution of ERK-1/2 and induction of e/
iNOS.
© 2006 Elsevier B.V. All rights reserved.Keywords: Metformin; Osteoblast; Osteoporosis; Diabetes mellitus1. Introduction
Metformin is one of the insulin-sensitizing agents most
commonly used for the management of different conditions
associated with insulin-resistance, such as type 2 diabetes,
metabolic syndrome and polycystic ovary syndrome. Metfor-
min is an anti-hyperglycaemic biguanide, which has been
widely used for decades. Nevertheless, the precise mechanism
of action of metformin remains unclear. It is considered an
insulin-sensitizing drug, lowering glycaemic levels without
increasing insulin secretion (Garber, 2004). Several sites of
action have been proposed for metformin, including decreased
hepatic glucose output, increased peripheral glucose uptake
and improved insulin secretion (Bailey and Turner, 1996).
Metformin has also been shown to have several beneficial
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doi:10.1016/j.ejphar.2006.02.030in lipid profile, decreased propensity towards intravascular
thrombosis by lowering concentrations and activity of
plasminogen activator inhibitor-1, decreasing platelet aggre-
gation and adhesion, increasing tissue plasminogen activator
activity, and improving endothelial dysfunction. In a clinical
setting, metformin is an oral anti-hyperglycaemic agent which
has been firmly associated with a long-term decrease in
macrovascular events in type 2 diabetic patients (UKPDS 34,
1998).
Several studies have shown both in vivo and in vitro that
metformin can act through activation of tyrosine kinases
(Dominguez et al., 1996) and AMP-activated protein kinase
(AMPK) (Zhou et al., 2001; Musi et al., 2002). AMPK
phosphorylates multiple enzymes involved in several bio-
synthetical pathways such as acetyl-CoA carboxylase, hydro-
xymethylglutaryl-CoA reductase, glycogen synthase and
endothelial nitric oxide synthase (eNOS). AMPK activation
results in an increase in cellular glucose transport both in liver
and muscle cells, and in a decrease in hepatic glucose
production, cholesterol synthesis and triglyceride synthesis
(Kemp et al., 1999; Chen et al., 1999; Zou et al., 2004).
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remodelling, through the precise and localized coupling of
resorption (removal of aged material) with replacement by
newly formed bone. This process requires the interaction
between different cell types such as osteoblasts, macrophages
and osteoclasts, which is regulated in turn by a variety of
biochemical and mechanical factors (Hill, 1998).
Various signal-transduction mechanisms have been shown to
be particularly relevant to the growth and development of bone
cells. Nitric oxide (NO) is a signalling molecule constitutively
produced in bone cells, and which increases in response to
several stimuli such as sex hormones, mechanical strain and
proinflammatory cytokines. NO is generated by the nitric oxide
synthase enzymes (NOS). Two isoforms of NOS, inducible
(iNOS) and endothelial (eNOS), are expressed in osteoblasts
(Van't Hof and Ralston, 2001; Rubin et al., 2003). It has been
previously demonstrated that eNOS knockout mice have
reduced bone formation, a decrease in osteoblast number and
diminished mineral apposition rate, showing that the eNOS
pathway plays a central role in bone metabolism by modulating
osteoblastic function (Armour et al., 2001).
Additionally, in osteoblasts, the mitogen-activated protein
kinase (MAPK) pathway constitutes an important transducer of
extracellular matrix-integrin signals to the nucleus (Gumbiner,
1996) and the subsequent stimulation of Cbfa1-dependent
transcription (Xiao et al., 2002). Extracellular signal-regulated
kinase (ERK) 1/2 (p42 and p44 MAPK) are strongly activated
by growth factors, serum, bisphosphonates and estrogen in bone
cells (Plotkin et al., 2005a,b). ERK1/2 are distributed
throughout non-stimulated cells, but upon stimulation a
significant proportion of ERK1/2 accumulates in the nucleus
(Chen et al., 2005). The mechanisms involved in nuclear
accumulation of ERK1/2 are still obscure, although nuclear
retention, dimerization, phosphorylation and release from
cytoplasmic anchors have been shown to play a role controlling
cell differentiation and cell behavior (Xiao et al., 2002; Plotkin
et al., 2005a,b; Roux and Blenis, 2004). In addition, it has been
suggested that the kinetics of ERK phosphorylation and the
length of time that P-ERKs are retained in the nucleus are
responsible for pro- versus anti-apoptotic effects of estrogens on
different cell types of bone (Chen et al., 2005).
In the present work, we have evaluated the effects of
metformin on the growth and differentiation of osteoblasts in
culture. In addition, we have also investigated possible
mechanisms of action of metformin, such as the expression of
eNOS and iNOS and the activation of ERK 1/2.
2. Materials and methods
2.1. Materials
Dulbecco's modified Eagle's medium (DMEM), trypsin-
EDTA and fetal bovine serum (FBS) were obtained from Gibco
(Invitrogen, Buenos Aires, Argentina). Tissue culture dispos-
able material was from Nunc (Tecnolab, Buenos Aires,
Argentina). Goat polyclonal anti-ERK1/2 antibodies, a mono-
clonal anti-P-ERK antibody and polyclonal antibodies againsteNOS and iNOS were from Santa Cruz Biotechnology Inc.
(Santa Cruz, CA, USA). Di-amino-bencidine, as well as Sirius
red and Alizarin red S dyes were obtained from Sigma-Aldrich
(Buenos Aires, Argentina). Metformin was donated by Quimica
Montpellier (Buenos Aires, Argentina). All other chemicals and
reagents were purchased from commercial sources and were of
analytical grade.
2.2. Cell culture and incubations
UMR106 rat osteosarcoma cells and MC3T3E1 mouse
calvaria-derived cells were grown in DMEM containing 10%
FBS, 100U/ml penicillin and 100μg/ml streptomycin at 37°C
in a 5% CO2 atmosphere (McCarthy et al., 1997). Cells were
seeded on 75-cm2 flasks, subcultured using trypsin-EDTA and
replated on multi-well plates. The UMR106 cell line has been
shown to conserve certain characteristics of differentiated
osteoblastic phenotype (Partridge et al., 1983). In the case of
non-transformed MC3T3E1 cells, previous studies have
demonstrated that expression of osteoblastic markers begins
after culturing the cells with medium supplemented by 5mM β-
glycerol-phosphate and 145μM ascorbic acid (Quarles et al.,
1992). Under these culture conditions, alkaline phosphatase
activity begins to be expressed after 1week and reaches a
maximum after 2weeks, while mineralization is achieved after
extending the culture to 3weeks. However, the cells only
undergo active replication during the first 5days of incubation.
For proliferation experiments with both cell lines and
differentiation experiments with UMR106 osteoblasts, cells
on multi-well plates were incubated in serum-free medium with
different doses of metformin, during the periods of time
indicated in the legends of figures. For type-I collagen secretion
and mineralization experiments with MC3T3E1 osteoblasts,
cells were cultured for 2 or 3weeks, respectively, in DMEM/
FBS (with or without different doses of metformin) supple-
mented with β-glycerol-phosphate and ascorbic acid, changing
this complete medium every 2days. For alkaline phosphatase
expression experiments with MC3T3E1 osteoblasts, cells were
cultured for 2weeks in DMEM/FBS supplemented with β-
glycerol-phosphate and ascorbic acid changing the medium
every 2days, after which they were serum-starved and
incubated in DMEM with or without different doses of
metformin for an additional 24h.
2.3. Cell proliferation assay
Cell proliferation was determined using the crystal violet
mitogenic bioassay as described previously (Okajima et al.,
1992), with some modifications. Briefly, cells were grown in
48-well plates and incubated with different concentrations of
metformin in serum-free DMEM, according to the figure
legends. Then, the monolayers were washed with phosphate-
buffered saline (PBS) and fixed with 5% glutaraldehyde/PBS
at room temperature for 10min. After that, they were stained
with 0.5% crystal violet/25% methanol for 10min. The dye
taken up by the cells was extracted using 0.5ml/well 0.1M
glycine/HCl buffer, pH 3.0/30% methanol and transferred to
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sample dilution. We have previously shown that, under these
conditions, this colorimetric bioassay strongly correlates with
cell proliferation measured by cell counting in Neubauer
chambers (Cortizo and Etcheverry, 1995; Etcheverry et al.,
1997).
2.4. Assays for osteoblast differentiation and mineralization
Osteoblastic differentiation was evaluated by two markers:
alkaline phosphatase activity and the quantitation of type-I
collagen production. Alkaline phosphatase activity was
assayed as we have previously described (Cortizo and
Etcheverry, 1995; Molinuevo et al., 2004). Briefly, the cells
were incubated overnight with different doses of metformin in
serum-free DMEM. The cell layer was then washed with PBS
and solubilized in 0.5ml 0.1% Triton X-100. Aliquots of the
total cell extract were used for protein determination by the
Bradford (1976) technique. Measurement of alkaline phos-
phatase activity was carried out by spectrophotometric
determination of initial rates of hydrolysis of para-nitrophe-
nyl-phosphate to para-nitrophenol at 37°C for 10min. The
production of para-nitrophenol was determined by absorbance
at 405nm. Under these experimental conditions, the product
formation was linear for 15min. Collagen production was
evaluated with a Sirius red-based colorimetric micro-assay
(Tullberg-Reinert and Jundt, 1999): cells were fixed in
Bouin's fluid for 1h, washed with water and stained with
Sirius red dye for 1h. The stained material was dissolved in
0.1N sodium hydroxide and absorbance read at 550nm.
Mineralized nodules in the extracellular matrix of MC3T3E1
osteoblasts were stained with Alizarin red S (Ueno et al.,
2001). The dye taken up by extracellular calcium deposits
was dissolved in 0.1N sodium hydroxide and quantified
spectrophotometrically at 548nm.
2.5. Western blot analysis of P-ERK and NOS
Metformin-induced regulation of ERK 1/2 activation, as well
as eNOS and iNOS expression, were evaluated by Western blot
(Barrio et al., 2003; Cortizo et al., 2000). In these experiments,
osteoblastic cells growing in serum-free medium with the
addition of different concentrations of metformin were lysated
in Laemmli's buffer (Laemmli et al., 1979) and the protein
content was evaluated by the method of Lowry (Lowry et al.,
1951). These lysates were heated at 100°C for 3min and
aliquots corresponding to 30μg of total protein were subjected
to 12% SDS-PAGE. The separated proteins were then electro-
transferred to PVDF membranes. After washing and blocking,
the membranes were incubated with a monoclonal anti-P-ERK
antibody, a polyclonal antibody that recognizes both phosphor-
ylated and unphosphorylated ERK1/2, or polyclonal antibodies
against eNOS or iNOS. Blots were developed using di-amino-
bencidine-peroxidase staining. The intensity of the specific
bands was quantified by densitometry after scanning of the
membranes. Images were analysed using the Scion-beta 2
program.2.6. Localization of P-ERK and i/eNOS by immunofluorescence
analysis
Cells grown on coverslips with or without different
concentrations of metformin were fixed in 4% para-formalde-
hyde in PBS, blocked and incubated with a monoclonal anti-P-
ERK antibody, polyclonal anti-iNOS or polyclonal anti-eNOS
(1:200 each) at 4°C for 16h. After washing, a secondary FITC-
labelled antibody (1:200) was added for 2h at room
temperature. Coverslips were mounted in a Vectastain mounting
liquid and the distribution of the specific protein was imaged
using a Nikon-5000 fluorescence microscope and a digital
camera.
2.7. Statistical analysis
Three independent experiments were run for each experi-
mental condition. Results are expressed as the mean±S.E.M.
One-way ANOVA with Dunnett's post-test was performed
using GraphPad InStat version 3.05.GraphPad Software, San
Diego, California, USA. P<0.05 was accepted as statistically
significant when compared with untreated control (0μM
metformin).
3. Results
3.1. Metformin regulates osteoblastic growth, differentiation
and mineralization
To investigate the effect of metformin on growth and
differentiation of osteoblasts, two osteoblast-like cell lines
(MC3T3E1 and UMR106) were used. Treatment of each cell
line with metformin (25–500μM) for 24h led to a dose-
dependent increase of cell proliferation as determined by the
crystal violet bioassay. Fig. 1A shows that maximal stimulation
was reached at a concentration of 200μM (115% of basal) for
both cell lines.
To examine the effect of metformin on osteoblast
differentiation, alkaline phosphatase activity and type-I
collagen production were evaluated. Metformin (25–
500μM) had no effect on alkaline phosphatase activity in
UMR106 cells (data not shown). Pre-osteoblastic MC3T3E1
cells were differentiated in the presence of ascorbic acid and
β-glycerol-phosphate during 2weeks. After this culture
period, differentiated MC3T3E1 osteoblasts were treated
with metformin (25–500μM) for 24h. Fig. 1B shows that
the anti-diabetic drug significantly stimulated alkaline phos-
phatase in a dose-dependent manner, with a maximum at
100μM concentration (145% of basal). In addition, metformin
dose-dependently stimulated the production of a type-I
collagenous matrix both by the UMR106 (113% of basal)
and the MC3T3E1 cell lines (128% of basal) (Fig. 1C).
Furthermore, the effect of this anti-diabetic compound on the
ability of MC3T3E1 cells to mineralize the matrix was
assessed after 3weeks of culture in the presence of β-glycerol
phosphate and ascorbic acid. Fig. 1D shows that metformin at
500μM significantly stimulated (385% basal) calcium
Fig. 1. Effect of metformin on proliferation, differentiation and mineralization of osteoblastic cells. (A) MC3T3e1 and UMR106 osteoblasts were incubated in serum-
free media in the presence of different concentrations of metformin for 24h. Subsequently, proliferation was evaluated by the crystal violet bioassay. (B) MC3T3E1
pre-osteoblasts were differentiated during 2 weeks in the presence of βGP and AA. ALP was assessed after 24-h incubation in serum-free media with different doses of
metformin, as described in Section 2. (C) MC3T3E1 cells were differentiated for 2 weeks in βGP and AA-supplemented media and different concentrations of
metformin, and UMR106 were incubated for 48 h in serum-free media with different doses of metformin. After these culture periods, type-I collagen production was
evaluated by Sirius red staining. (D) MC3T3E1 osteoblasts were cultured for 3 weeks in βGP and AA-supplemented media and different concentrations of metformin.
Mineralized nodules were quantitated by Alizarin-Red S staining, as described in Section 2. Data represent mean±S.E.M. #p<0.05, ⁎p<0.01, when compared with
untreated control.
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red S staining.
Our results indicate that metformin can act as a weak
mitogen in osteoblastic cells, and that the long-term exposure of
osteoblastic cultures to metformin induces osteogenic effects.
3.2. Metformin acutely induces ERK phosphorylation and its
subcellular redistribution
P42/44 MAPK is an important signal transduction pathway
involved in several growth factor effects. In order to
investigate the mechanism by which metformin affects
osteoblastic growth and differentiation, osteoblastic cells
were treated with 1mM metformin for different periods oftime. At the end of this incubation, the activation/phosphor-
ylation of ERK was analyzed by Western immunoblot and
the intracellular localization of P-ERK by immunofluores-
cence, using a specific anti-P-ERK antibody. In MC3T3E1
osteoblasts, metformin significantly increased P-ERK after
5min, an activation that was sustained for 60min and
decreased to basal levels after 90min of incubation (Fig. 2A).
However, there was no change in total ERK protein, as
assessed by immunoblots using an anti-ERK antibody.
Immunofluorescence experiments showed that P-ERK was
mainly present in the cytoplasm with a punctate-granular
staining in the control non-treated osteoblasts (Fig. 2B),
although a minor proportion of fluorescence appeared
associated with the nucleus (22% of stained cells). After
Fig. 2. Effect of metformin on ERK activation and distribution. MC3T3E1 cells were serum starved for 24h and incubated with 1 mM metformin for different periods
of time. (A) Cell lysates were collected, and both total and phosphorylated ERK 1/2 phosphorylation was assessed by Western immunoblot analysis. (B) P-ERK
localization in the cells was assessed by indirect immunofluorescence. At the indicated times, cells were fixed and incubated with an anti-P-ERK antibody. Obj. 100×.
Data represent mean±S.E.M. #p<0.05, ⁎p<0.01, when compared with untreated control.
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the nuclei-associated fluorescence was observed (43% of
stained cells). This effect disappeared after 90-min incuba-
tion. In the case of UMR106 osteosarcoma cells, treatment
with metformin induced effects on ERK phosphorylation andredistribution, which were identical to those observed for
MC3T3E1 osteoblasts (data not shown). All in all, these
results suggest that metformin induces the activation and
redistribution of P-ERK in a transient manner in osteoblastic
cells.
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Nitric oxide is known to be implicated in the metabolism of
bone, especially as a mediator of cytokine effects on the
remodeling of bone tissue. Thus, we investigated whether
metformin had any effect on the expression of eNOS and iNOS
in MC3T3E1 osteoblasts, as evaluated by Western immunoblot
and immunofluorescence.
In the non-transformed MC3T3E1 osteoblasts, 24-h incu-
bation with 50–500μM metformin stimulated the expression
of both NOS isoforms in a dose-dependent manner (Fig. 3AFig. 3. Effect of metformin on endothelial and inducible NOS. MC3T3E1 cells were
iNOS presence was observed by fixing and staining cells with anti-eNOS or anti-
Alternatively, cells were lysated and the expression of e/iNOS was analysed by Wes
untreated control.and B). By immunofluorescent analysis of control MC3T3E1
cells, eNOS was shown to localize principally in the
cytoplasm in a diffuse and patchy pattern, while iNOS was
also cytoplasmic but with a more punctuate pattern.
Incubation with 100μM metformin increased both eNOS-
and iNOS-associated fluorescence, showing a more homoge-
neous cytoplasmic distribution (Fig. 3A). A dose-dependent
effect of metformin on eNOS and iNOS expression in
MC3T3E1 cells was shown by western immunoblot (Fig 3B).
Endothelial NOS stimulation by metformin was biphasic,
showing a peak at 100μM concentration. On the other hand,incubated in serum-free media with different doses of metformin for 24h. (A) e/
iNOS antibodies and observed in a fluorescence microscopy. Obj. 100×. (B)
tern immunoblot. Data represent mean±S.E.M. ⁎p<0.01, when compared with
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dependent, reaching a plateau after 200μM doses.
4. Discussion
Osteoporosis, one of the most prevalent metabolic bone
diseases in developed countries, is a major public health
problem due to its association with fragility fractures (Chau et
al., 2003). Several studies have reported skeletal involvement
in diabetic patients; however, the mechanisms underlying this
association are poorly understood (Chau et al., 2003;
Carnevale et al., 2004). Krakauer et al. (1995) showed in a
12-year follow-up study that osteoblastic extracellular matrix
formation and mineralization were reduced by 70–75% in
patients with diabetes mellitus. These investigators proposed
that this impaired osteoblastic function could be the cause of
the osteopenia observed in their series of type 1 diabetic
patients and of the decrease in bone remodeling observed in
their series of type 2 diabetic patients. Previous research has
identified as a possible cause for these diabetes-associated
bone alterations, the pathological accumulation of advanced
glycation end-products on bone extracellular matrix proteins
(McCarthy et al., 1997; Tomasek et al., 1994; Katayama et al.,
1996). Advanced glycation end-products are irreversibly and
non-enzymatically formed on long-lived proteins, accumulate
in diabetic patients as a consequence of chronic hyperglycemia
and oxidative stress, and are thought to be partly responsible
for the macrovascular and microvascular complications of
diabetes mellitus (Vlassara and Palace, 2002). In previous
studies, we have shown that advanced glycation end-products-
modified type-I collagen decreases the differentiation, miner-
alization and long-term survival of MC3T3E1 osteoblasts in
culture, probably through the interaction of advanced glyca-
tion end-products with specific receptors (McCarthy et al.,
2001a,b). Advanced glycation end-products have also been
shown to prevent the differentiation of human mesenchymal
stem cells into bone-forming osteoblasts (Kume et al., 2005).
In view of the association which has been established
between long-standing diabetes mellitus and the loss of bone
mineral density and/or quality, it is clinically relevant to
investigate the effects of widely used anti-diabetic drugs on
the metabolism of bone cells. Recently, detrimental effects of
the insulin-sensitizing drug rosiglitazone have been demon-
strated by in vitro and in vivo studies on bone tissue:
rosiglitazone was shown to promote commitment of osteo-
progenitor cells to the adipocyte lineage while inhibiting
osteoblastogenesis and bone formation (Lecka-Czernik et al.,
1999, 2002).
There have been no previous studies investigating the
possible actions on bone cells of metformin, an insulin-
sensitizing drug widely used for the treatment of diabetic
patients. In the present study, we have studied the effects of
metformin on the growth and development of two osteoblast-
like cell lines. Our present results demonstrate for the first time
that metformin exerts osteogenic actions on osteoblasts in
culture. Evidence for this notion is based on several observa-
tions: (a) metformin acts as a weak mitogen, stimulatingosteoblastic proliferation; (b) although metformin does not
affect alkaline phosphatase activity in the UMR106 osteosar-
coma cell line, it increases this marker of osteoblastic
differentiation in the non-transformed MC3T3E1 cells; (c)
metformin dose-dependently stimulates type-I collagen pro-
duction in both cell lines; and (d) after 3weeks of culture,
metformin strongly induces the formation of nodules of
mineralization in MC3T3E1 osteoblasts. Thus, in our in vitro
experimental conditions, this anti-diabetic drug not only
induces osteoblast growth and differentiation, but also has the
ability to increase mineralization of the extracellular matrix. In
vivo studies are needed to investigate whether metformin also
has bone-preserving effects opposing the development of
diabetic osteopenia and osteoporosis.
Different authors have investigated the effects of metformin
on the proliferation of other cell types. This biguanide did not
influence cell proliferation in cultured arterial smooth muscle
cells, human dermal fibroblasts, umbilical artery-derived
smooth muscle cells or 3T3 fibroblastic cells (Peuler et al.,
1996; Petty and Pearson, 1992). In the present in vitro study, we
present data that clearly shows a proliferative effect of
metformin on osteoblast-like cells, in a concentration range
similar to that used by other authors (Peuler et al., 1996; Petty
and Pearson, 1992).
Our present results also demonstrate that metformin induces
osteoblastic differentiation, as assessed by two well-established
markers: alkaline phosphatase and type-I collagen production.
However, no effect was observed by metformin on the alkaline
phosphatase activity of UMR106 cells. This could be due to the
fact that UMR106 osteosarcoma cells greatly over-express
alkaline phosphatase in their basal state (100-fold greater than
MC3T3E1 cells), so it is not surprising that metformin has no
effect on alkaline phosphatase activity in these cells. In addition,
a sharp increase was observed in the formation of nodules of
mineralization in long-term cultures of MC3T3E1 osteoblasts
treated with metformin. In our experimental model, these
osteogenic effects of metformin may be mediated by the
secretion of soluble cytokines and/or growth factors into the
conditioned media. Further studies are necessary to investigate
if metformin addition is capable of modifying growth factor
secretion by osteoblasts in culture.
In order to investigate possible intracellular mechanisms
which could be mediating the osteogenic effects exerted by
metformin on osteoblasts, we first evaluated the ERK pathway.
Phosphorylation (activation) and intracellular redistribution of
ERK-1/2 have been identified as established transduction
mechanisms for various agents acting on bone cells, such as
bisphosphonates, estrogen, parathyroid hormone and mechan-
ical stimulation (Plotkin et al., 2005a,b, 2002). The data
presented in this study shows that ERK-1/2 is phosphorylated
after metformin treatment, in a time-dependent manner, in both
cell lines. In addition, a nuclear translocation of P-ERK was
observed after incubating the osteoblasts with metformin for
15–30min, with P-ERK returning to the cytoplasm after
90min. Duration and localization of MAPK signals are
normally regulated during the proliferation and differentiation
of many cell types (Pouyssegur et al., 2002). In particular, they
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estrogen on different bone cell types (Chen et al., 2005). To
address this issue in particular, in the present study, we also
investigated the possible effect of metformin on the apoptosis
of osteoblasts in culture. However, we were unable to find any
effect of metformin per se on the apoptosis of UMR106 and
MC3T3E1 osteoblastic cell lines (data not shown). Thus, the
metformin-induced ERK-1/2 phosphorylation and relocaliza-
tion could be associated with the observed increase in
osteoblastic growth and development. The MAPK signaling
pathway is known to regulate the activity of different
transcription factors, which are subsequently involved in the
regulation of proliferation, apoptosis and differentiation
(Burdon et al., 2002). Further studies are necessary to evaluate
this possibility.
Another signaling pathway which could be affected by
metformin in osteoblasts is the enzymatic generation of NO by
endothelial and inducible isoforms of NOS. Nitric oxide is
constitutively produced by osteoblasts, and has been shown to
modulate bone remodeling (Van't Hof and Ralston, 2001;
Collin-Osdoby et al., 1995). Our group and other investigators
have previously suggested that NO has biphasic effects on
osteoblasts (Cortizo et al., 2000; Collin-Osdoby et al., 1995;
Mancini et al., 2000). Constitutive or low levels of NO can be
effective mediators of osteoblastic growth and differentiation;
however, overproduction of NO leads to osteoblastic injury. We
have also shown that MC3T3E1 osteoblasts express readily
detectable levels of eNOS and iNOS (Cortizo et al., 2000). In
the present study, we demonstrate that metformin increases the
expression of both NOS isoforms in a dose-dependent manner,
with maximal stimulation at 100μM of metformin. This effect
was found to closely parallel the metformin-induced increase in
osteoblastic proliferation, suggesting a link between NO
production and cell growth in this cell line. Interestingly,
other authors have shown that hepatocyte growth factor can
exert effects on human endothelial cells, by sequentially
inducing eNOS expression, NO production and MAPK
phosphorylation (activation), which in turn increases cellular
proliferation (Kuhlmann et al., 2005).
In conclusion, these results show for the first time a direct
osteogenic effect of metformin on osteoblasts in culture and
suggest that these actions could be partly mediated by
activation/redistribution of ERK-1/2 and induction of e/iNOS.
These potentially bone-preserving effects of metformin could
be particularly relevant in the clinical setting of diabetic
osteopenia and osteoporosis.
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